Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MUC1-aptamer S2.2 is a 25-nucleotide single-stranded DNA (ssDNA) aptamer that selectively binds to the Mucin 1 (MUC1) glycoprotein with high affinity (Kd = 0.135 nM). It specifically targets the APDTRPAPG sequence within the variable number tandem repeat (VNTR) region of MUC1, a protein that is frequently overexpressed and aberrantly glycosylated in various adenocarcinomas. The aptamer's unique three-dimensional structure allows it to distinguish MUC1-expressing cancer cells, such as A-549 lung cancer cells, from normal tissues. In research settings, S2.2 is primarily utilized as a targeting moiety to deliver cytotoxic agents like doxorubicin or imaging contrast agents directly to tumor sites, aiming to improve therapeutic indices and diagnostic precision.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MUC1-aptamer S2.2.